Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 6, pp. 1498-1511
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Tomiko Oskotsky, Ivana Marić, Alice Tang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133090-e2133090
Open Access | Times Cited: 127
Mechanisms of action of fluvoxamine for COVID-19: a historical review
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 1898-1907
Open Access | Times Cited: 109
The acid sphingomyelinase/ceramide system in COVID-19
Johannes Kornhuber, Nicolas Hoertel, Erich Gulbins
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 307-314
Open Access | Times Cited: 97
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan, Roohangiz Nashibi, Mohammad‐Reza Mahmoudian‐Sani, et al.
European Journal of Pharmacology (2021) Vol. 914, pp. 174615-174615
Open Access | Times Cited: 88
COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
Marc D. Binder, Victor Mazereel, Marc Stroobants, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 57
Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro
Senem Merve Fred, Suvi Kuivanen, Hasan Uğurlu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 51
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection
Peiran Chen, Mandi Wu, Yaqing He, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 31
Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies
Farigol Hakem Zadeh, Daniel R. Wilson, Devendra K. Agrawal
Archives of Microbiology & Immunology (2023) Vol. 07, Iss. 02
Open Access | Times Cited: 27
Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
Nicolas Hoertel, Marina Sánchez‐Rico, Céline Cougoule, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 12, pp. 7098-7099
Open Access | Times Cited: 54
Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Nicolas Hoertel
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2136510-e2136510
Open Access | Times Cited: 43
Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort
Catherine L. Clelland, Krista Ramiah, Louisa J. Steinberg, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System
Katlyn Nemani, Sharifa Z. Williams, Mark Olfson, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2210743-e2210743
Open Access | Times Cited: 29
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Kenji Hashimoto
Discover Mental Health (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 20
Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism
Bernadette Breiden, Konrad Sandhoff
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9001-9001
Open Access | Times Cited: 37
Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
Nicolas Hoertel, David R. Boulware, Marina Sánchez‐Rico, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2242140-e2242140
Open Access | Times Cited: 26
Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: a multicenter retrospective observational study
Marina Sánchez‐Rico, Pedro de la Muela, Juan José Herrera-Morueco, et al.
Journal of Travel Medicine (2022) Vol. 29, Iss. 3
Open Access | Times Cited: 24
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Nicolas Hoertel, Marina Sánchez‐Rico, Johannes Kornhuber, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5882-5882
Open Access | Times Cited: 24
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Bradley A. Fritz, Nicolas Hoertel, Eric J. Lenze, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: current scenario and anticipated trends
Ishfaq Hassan Mir, Chinnasamy Thirunavukkarasu
Archives of Toxicology (2023) Vol. 97, Iss. 8, pp. 2069-2087
Open Access | Times Cited: 14
Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity
Samar Sami Alkafaas, Abanoub Mosaad Abdallah, Mai Helmy Hassan, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection
Shaymaa Elsayed Khater, Ahmed El‐Khouly, Hend Mohamed Abdel‐Bar, et al.
International Journal of Pharmaceutics (2021) Vol. 607, pp. 121023-121023
Open Access | Times Cited: 29
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Udo Bonnet, Georg Juckel
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 284-292
Open Access | Times Cited: 22
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model
David Péricat, Stephen Adonai Leon‐Icaza, Marina Sánchez‐Rico, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13623-13623
Open Access | Times Cited: 22
Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France
Nicolas Hoertel, Marina Sánchez‐Rico, Pedro de la Muela, et al.
Biological Psychiatry Global Open Science (2022) Vol. 3, Iss. 1, pp. 56-67
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top